Effects of statins on endothelial function in patients with coronary artery disease

Clinical Cardiology

Volumn 32, Issue 4, 2009, Pages 193-198

  Simova, Iana I ^a   Denchev, Stefan V ^a   Dimitrov, Simeon I ^a  

^a UNIVERSITY HOSPITAL ALEXANDROVSKA   (Bulgaria)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; MEVINOLIN; SIMVASTATIN;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; BRACHIAL ARTERY; CLINICAL FEATURE; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; DRUG EFFECT; FEMALE; FLOW MEDIATED DILATATION; HUMAN; MAJOR CLINICAL STUDY; MALE; TREATMENT RESPONSE; VASCULAR ENDOTHELIUM; VASODILATATION;

BLOOD FLOW VELOCITY; BRACHIAL ARTERY; CORONARY ARTERY DISEASE; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LASER-DOPPLER FLOWMETRY; MALE; MIDDLE AGED; REGIONAL BLOOD FLOW; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 64849085417     PISSN: 01609289     EISSN: None     Source Type: Journal    
DOI: 10.1002/clc.20316     Document Type: Article

References (10)

1. Celermajer DS, Sorensen KE, Gooch VM, et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet. 1992;340:1111-1115.
2. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
3. Jarvisalo MJ, Toikka JO, Vasankari T, et al. HMG CoA reductase inhibitors are related to improved systemic endothelial function in coronary artery disease. Atherosclerosis. 1999;147:237-242.
4. De Backer G, Ambrosioni E, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). Eur J Cardiovasc Prev Rehabil. 2003;10:S1-S78.
5. Corretti M, Anderson T, Benjamin E, et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery. A report of the international brachial artery reactivity task force. J Am Coll Cardiol. 2002;39: 257-265.
6. Simova I, Nossikov A, Denchev S. Interobserver and intraobserver variability of flow mediated vasodilatation of the brachial artery. Echocardiography. 2008;25:77-83.
7. Pearson TA, Laurora I, Chu H, Kafonek S. The lipid treatment assessment project (L-TAP): a multicentre study to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med. 2000;160:459-467.
8. Expert Panel on Detection, Evaluation, and Treatment High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment high blood cholesterol in adults (adult treatment panel III). JAMA. 2001;285:2486-2497.
9. EUROASPIRE II Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J. 2001;22:554-572.
10. Vogel RA, Nissen AE, Weiss RJ. Endothelial function, low-density lipoprotein, and moderate and intensive cholesterol lowering in coronary artery disease: a REVERSAL trial substudy. J Am Coll Cardiol. 2005;45:412A, Abstract 831-836.